Compare Lupin Ltd with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs AJANTA PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN AJANTA PHARMA LUPIN/
AJANTA PHARMA
 
P/E (TTM) x 47.5 22.5 211.2% View Chart
P/BV x 2.4 4.0 61.4% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 LUPIN   AJANTA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
AJANTA PHARMA
Mar-19
LUPIN/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,422 69.3%   
Low Rs720898 80.3%   
Sales per share (Unadj.) Rs369.5233.5 158.2%  
Earnings per share (Unadj.) Rs13.444.0 30.5%  
Cash flow per share (Unadj.) Rs37.452.2 71.7%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs303.7255.1 119.1%  
Shares outstanding (eoy) m452.4988.02 514.1%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.35.0 46.5%   
Avg P/E ratio x63.626.4 241.3%  
P/CF ratio (eoy) x22.822.2 102.6%  
Price / Book Value ratio x2.84.5 61.8%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m386,064102,081 378.2%   
No. of employees `00017.76.8 260.1%   
Total wages/salary Rs m31,5134,307 731.7%   
Avg. sales/employee Rs Th9,453.83,022.6 312.8%   
Avg. wages/employee Rs Th1,782.0633.4 281.3%   
Avg. net profit/employee Rs Th343.0569.1 60.3%   
INCOME DATA
Net Sales Rs m167,18220,554 813.4%  
Other income Rs m3,640211 1,726.9%   
Total revenues Rs m170,82220,765 822.7%   
Gross profit Rs m28,8225,664 508.8%  
Depreciation Rs m10,850721 1,505.3%   
Interest Rs m3,07812 26,537.1%   
Profit before tax Rs m18,5345,143 360.4%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,0171,273 708.3%   
Profit after tax Rs m6,0663,870 156.7%  
Gross profit margin %17.227.6 62.6%  
Effective tax rate %48.724.8 196.5%   
Net profit margin %3.618.8 19.3%  
BALANCE SHEET DATA
Current assets Rs m138,53611,812 1,172.8%   
Current liabilities Rs m61,2993,776 1,623.2%   
Net working cap to sales %46.239.1 118.2%  
Current ratio x2.33.1 72.3%  
Inventory Days Days8477 108.3%  
Debtors Days Days11282 137.8%  
Net fixed assets Rs m127,51614,398 885.6%   
Share capital Rs m905175 516.0%   
"Free" reserves Rs m136,51722,277 612.8%   
Net worth Rs m137,42222,452 612.1%   
Long term debt Rs m66,4177 1,006,321.2%   
Total assets Rs m279,49426,962 1,036.6%  
Interest coverage x7.0444.3 1.6%   
Debt to equity ratio x0.50 164,413.1%  
Sales to assets ratio x0.60.8 78.5%   
Return on assets %3.314.4 22.7%  
Return on equity %4.417.2 25.6%  
Return on capital %8.923.0 38.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,41410,682 556.2%   
Fx outflow Rs m22,2822,102 1,060.1%   
Net fx Rs m37,1328,580 432.8%   
CASH FLOW
From Operations Rs m16,6603,748 444.5%  
From Investments Rs m-32,825-2,228 1,473.3%  
From Financial Activity Rs m7,441-1,475 -504.6%  
Net Cashflow Rs m-8,72445 -19,300.2%  

Share Holding

Indian Promoters % 46.6 73.8 63.1%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 1.6 729.0%  
FIIs % 31.9 7.6 419.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 17.0 59.4%  
Shareholders   98,259 20,968 468.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare LUPIN With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Oct 18, 2019 (Close)

TRACK LUPIN

LUPIN - J.B.CHEMICALS COMPARISON

COMPARE LUPIN WITH

MARKET STATS